ArticleNephron2022
Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis.
Article in Nephron, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.Frontiers in nephrology · 2026Pooled it
- Potential Roles of Escherichia coli in IgA Nephropathy: Evidence, Mechanistic Hypotheses and Microbiota-Targeted Strategies.Microbial biotechnology · 2026Review
- Article
- Time-Updated Hematuria and Kidney Disease Progression in IgAN.Kidney international reports · 2026Article
- Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.Clinical kidney journal · 2026Review
- Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Treatment patterns, clinical outcomes, and economic burden among patients with immunoglobulin A nephropathy (IgAN) in China.BMC nephrology · 2026Article
- Validation of 2 Prognostic Models to Predict Renal Allograft Outcome After IgA Nephropathy Recurrence.Kidney international reports · 2025Article
- Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.Journal of nephrology · 2025Article
- Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity.Clinical kidney journal · 2025Article
- Characterisation of IgA Nephropathy in an Australian Cohort.International journal of nephrology · 2025Article
- Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.Heliyon · 2024Review
- Clinical and Epidemiological Study of IgA Nephropathy in the Bulgarian Population: Insights into Disease Presentation and Potential Biomarkers.Journal of personalized medicine · 2024Article
- Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.Clinical kidney journal · 2023Review
- Detection of N‑glycoprotein associated with IgA nephropathy in urine as a potential diagnostic biomarker using glycosylated proteomic analysis.Experimental and therapeutic medicine · 2023Article
- Autoinflammatory diseases and the kidney.Immunologic research · 2023Review
- Post-hoc analysis of a tool to predict kidney failure in patients with IgA nephropathy.Journal of nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWithin 30 years, 20-50% of IgA nephropathy (IgAN) patients progress to end-stage kidney disease (ESKD). Identifying these patients can be difficult since renal function may deteriorate after being stable for years. The International IgAN Risk Prediction tool (IgAN-RPT) combines histologic lesions and clinical risk factors to predict renal outcome up to 5 or 7 years of follow-up. The clinical value beyond 7 years is unknown and microhematuria data has not been assessed.
methodsWe studied the long-term renal outcome of 95 Swedish IgAN patients from the derivation cohort for the IgAN-RPT. The median follow-up was 11.2 years. Microhematuria at baseline was defined as high-degree by microscopy measurement of >10 red blood cell/high-power field of view or urine dipstick grading of 2-3. Primary outcome was defined as a 50% decrease in estimated glomerular filtration rate or ESKD.
resultsThe mean predicted 5-year risk for increasing quartiles was 0.95%, 2.57%, 5.88%, and 23.31% and the observed 5-year-outcome was 0%, 0%, 0%, and 33.33%. During continued follow-up, 0%, 4.2%, 21.7%, and 75.0% of patients reached the primary outcome. ROC curve analysis identified the 5-year risk thresholds of under 4% and over 11% for very low and very high-risk patients, respectively. High-degree microhematuria was not significantly associated with renal outcome (p = 0.14).
conclusionsThe IgAN-RPT identifies long-term high- and low-risk patients, which can guide decisions on the frequency of clinical control visits and the selection of patients for clinical trials. Patients with intermediate risk remain a clinical challenge with an urgent need for novel biomarkers and treatments. Microhematuria could be a valuable marker of inflammatory activity, but measurement needs to be standardized for implementation in risk prediction tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.